Hitoshi Masuo
Shinshu University
9 Papers
4 Citations
Hitoshi Masuo is an academic researcher from Shinshu University. The author has contributed to research in topics: Medicine & Survival rate. The author has an hindex of 2, co-authored 9 publications.
Chat about Author
Papers
Contrast-enhancement ratio on multiphase enhanced computed tomography predicts recurrence of pancreatic neuroendocrine tumor after curative resection
Takuma Arai,Akira Kobayashi,Yasunari Fujinaga,Takahide Yokoyama,Akira Shimizu,Hiroaki Motoyama,Noriyuki Kitagawa,Tsuyoshi Notake,Tomoki Shirota,Kentaro Fukushima,Hitoshi Masuo,Masumi Kadoya,Shinichi Miyagawa +12 more
TL;DR: CER might be a useful predictor of disease recurrence in patients with pNETs and is evaluated using multiphase enhanced CT and to assess the impact of the CER on diseaseRecurrence after surgery.
12
Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Ductal Adenocarcinoma.
Koji Kubota,Akira Shimizu,Tsuyoshi Notake,Hitoshi Masuo,Kiyotaka Hosoda,Koya Yasukawa,Hikaru Hayashi,Kentaro Umemura,Atsushi Kamachi,Takamune Goto,Hidenori Tomida,Shiori Yamazaki,Yuji Soejima +12 more
TL;DR: In this article, the authors evaluated whether the lymphocyte-to-monocyte ratio (LMR) can predict the long-term outcomes for patients who were to undergo surgical resection of pancreatic ductal adenocarcinoma (PDAC).
8
•Journal Article
Multidisciplinary Approach for Progressive Xanthogranulomatous Pancreatitis: Case Report and Review of the Literature
TL;DR: A 23-year-old man is reported who was found to have xanthogranulomatous pancreatitis complicated by pancreas pseudocysts that infiltrated into spleen, stomach, transverse colon and omentum and the lesion persisted through medical treatments.
Adjuvant Chemotherapy with Gemcitabine for Resected Biliary Tract Cancer : A Single-Arm Phase 2 Study
Noriyuki Kitagawa,Hiroaki Motoyama,Akira Kobayashi,Takahide Yokoyama,Akira Shimizu,Tsuyoshi Notake,Kentaro Fukushima,Hitoshi Masuo,Takahiro Yoshizawa,Teruomi Tsukahara,Shinichi Miyagawa +10 more
- 10 Apr 2017
TL;DR: This study showed that the adjuvant chemotherapy Adjuvant Chemotherapy with Gemcitabine for Resected Biliary Tract Cancer : A Single-Arm Phase 2 Study showed that there was no significant difference in long-term outcomes between the two treatments.
1